المؤلفون: Brown J; DSA - Norwegian Radiation and Nuclear Safety Authority, Grini Næringspark 13, 1361 Østerås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway. Electronic address: justin.brown@dsa.no., Teien HC; Faculty of Environmental Sciences and Natural Resource Management, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Thørring H; DSA - Norwegian Radiation and Nuclear Safety Authority, Grini Næringspark 13, 1361 Østerås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Skipperud L; Faculty of Environmental Sciences and Natural Resource Management, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Hosseini A; DSA - Norwegian Radiation and Nuclear Safety Authority, Grini Næringspark 13, 1361 Østerås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Lind OC; Faculty of Environmental Sciences and Natural Resource Management, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Oughton D; Faculty of Environmental Sciences and Natural Resource Management, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway., Salbu B; Faculty of Environmental Sciences and Natural Resource Management, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway; Center for Environmental Radioactivity (CERAD) CoE, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Ås, Norway.

المصدر: The Science of the total environment [Sci Total Environ] 2024 Aug 25; Vol. 940, pp. 173503. Date of Electronic Publication: 2024 May 29.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0330500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1026 (Electronic) Linking ISSN: 00489697 NLM ISO Abbreviation: Sci Total Environ Subsets: MEDLINE

مواضيع طبية MeSH: Radioisotopes*, Radiation Monitoring ; Norway ; Ecosystem ; Cesium Radioisotopes/analysis ; Cesium Radioisotopes/metabolism ; Food Chain ; Animals ; Water Pollutants, Radioactive/analysis ; Risk Assessment ; Strontium Radioisotopes/analysis ; Strontium Radioisotopes/metabolism

المؤلفون: Sihver W; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Walther M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Ullrich M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Nitt-Weber AK; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Böhme J; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Reissig F; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Saager M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Zarschler K; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Neuber C; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Steinbach J; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Kopka K; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.; Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Mommsenstraße 4, 01069 Dresden, Germany., Pietzsch HJ; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.; Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Mommsenstraße 4, 01069 Dresden, Germany., Wodtke R; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany., Pietzsch J; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.; Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Mommsenstraße 4, 01069 Dresden, Germany.

المصدر: Bioconjugate chemistry [Bioconjug Chem] 2024 Sep 18; Vol. 35 (9), pp. 1402-1416. Date of Electronic Publication: 2024 Aug 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9010319 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4812 (Electronic) Linking ISSN: 10431802 NLM ISO Abbreviation: Bioconjug Chem Subsets: MEDLINE

مواضيع طبية MeSH: Triazoles*/chemistry , Triazoles*/pharmacokinetics , Fluorine Radioisotopes*/chemistry, Animals ; Humans ; Mice ; Gallium Radioisotopes/chemistry ; Radiopharmaceuticals/chemistry ; Radiopharmaceuticals/pharmacokinetics ; Radiopharmaceuticals/chemical synthesis ; Male ; Cell Line, Tumor ; Click Chemistry ; Tissue Distribution

المؤلفون: Pike S; Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2., Wuest M; Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2., Lopez-Campistrous A; Department of Surgery, University of Alberta, Edmonton, Canada T6G 2B7., Hu MY; Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2., Derda R; Department of Chemistry, University of Alberta, Edmonton, Canada T6G 2N4., Wuest F; Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2., McMullen T; Department of Surgery, University of Alberta, Edmonton, Canada T6G 2B7.

المصدر: Molecular pharmaceutics [Mol Pharm] 2024 Sep 02; Vol. 21 (9), pp. 4648-4663. Date of Electronic Publication: 2024 Aug 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Peptides, Cyclic*/chemistry , Receptor, Platelet-Derived Growth Factor alpha*/metabolism , Gallium Radioisotopes*/chemistry , Molecular Imaging*/methods, Humans ; Animals ; Cell Line, Tumor ; Mice ; Positron-Emission Tomography/methods ; Thyroid Neoplasms/diagnostic imaging ; Thyroid Neoplasms/metabolism ; Radiopharmaceuticals/chemistry ; Radiopharmaceuticals/pharmacokinetics ; Thyroid Cancer, Papillary/diagnostic imaging ; Thyroid Cancer, Papillary/metabolism ; Cell Movement ; Copper Radioisotopes/chemistry ; Mice, Nude ; Female

المؤلفون: Igarashi J; Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan., Ninomiya K; Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan., Zheng J; Institute for Radiological Science, National Institute for Quantum Science and Technology (QST), 491 Anagawa, Inage, Chiba 263-8555, Japan., Zhang Z; Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan., Fukuda M; Institute for Radiological Science, National Institute for Quantum Science and Technology (QST), 491 Anagawa, Inage, Chiba 263-8555, Japan.; Research Department, Fukushima Prefectural Centre for Environmental Creation, 10-2 Fukasaku, Miharu Town, Fukushima 963-7700, Japan., Aono T; Institute for Radiological Science, National Institute for Quantum Science and Technology (QST), 491 Anagawa, Inage, Chiba 263-8555, Japan., Minowa H; The Jikei University School of Medicine, 3-25 Nishishinbashi, Minato Ward, Tokyo 105-0003, Japan., Yoshikawa H; The Jikei University School of Medicine, 3-25 Nishishinbashi, Minato Ward, Tokyo 105-0003, Japan., Sueki K; Graduate School of Pure and Material, Tsukuba University, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan., Satou Y; Collaborative Laboratories for Advanced Decommissioning Science, Japan Atomic Energy Agency, 790-1 Otsuka, Motooka, Tomioka, Futaba, Fukushima 979-1151, Japan., Shinohara A; Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan.; Faculty of Health Science, Osaka Aoyama University, 2-11-1 Niina, Minoh, Osaka 562-8580, Japan.

المصدر: Environmental science & technology [Environ Sci Technol] 2024 Aug 20; Vol. 58 (33), pp. 14823-14830. Date of Electronic Publication: 2024 Aug 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0213155 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5851 (Electronic) Linking ISSN: 0013936X NLM ISO Abbreviation: Environ Sci Technol Subsets: MEDLINE

مواضيع طبية MeSH: Fukushima Nuclear Accident* , Plutonium* , Strontium Radioisotopes*, Nuclear Power Plants ; Radiation Monitoring ; Japan ; Cesium Radioisotopes

المؤلفون: Luo Y; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China., Jin W; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China., Wang R; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China., Zhao R; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China., Zhu L; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China., Kung HF; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.

المصدر: Journal of medicinal chemistry [J Med Chem] 2024 Aug 08; Vol. 67 (15), pp. 13491-13506. Date of Electronic Publication: 2024 Jul 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Gallium Radioisotopes*/chemistry , Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/metabolism , Glutamate Carboxypeptidase II*/metabolism , Antigens, Surface*/metabolism , Lutetium*/chemistry, Male ; Animals ; Humans ; Mice ; Radioisotopes/chemistry ; Positron Emission Tomography Computed Tomography ; Radiopharmaceuticals/chemistry ; Radiopharmaceuticals/chemical synthesis ; Radiopharmaceuticals/pharmacokinetics ; Cell Line, Tumor ; Tissue Distribution ; Mice, Nude ; Tumor Hypoxia

المؤلفون: Kuo PH; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Morris MJ; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Hesterman J; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Kendi AT; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Rahbar K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Wei XX; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Fang B; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Adra N; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Garje R; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Michalski JM; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Chi K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., de Bono J; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Fizazi K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Krause B; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Sartor O; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Tagawa ST; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Ghebremariam S; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Brackman M; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Wong CC; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Catafau AM; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Benson T; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Armstrong AJ; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.)., Herrmann K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer Center, Münster and Essen, Germany (K.R.); Dana-Farber Cancer Institute, Boston, Mass (X.X.W.); Astera Cancer Care, East Brunswick, NJ (B.F.); Indiana University Simon Comprehensive Cancer Center, Indianapolis, Ind (N.A.); Miami Cancer Institute, Baptist Health South Florida, Miami, Fla (R.G.); Washington University, St. Louis, Mo (J.M.M.); British Columbia Cancer Agency, Vancouver, British Columbia, Canada (K.C.); The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom (J.d.B.); Gustave Roussy Institute, University of Paris-Saclay, Villejuif, France (K.F.); Rostock University Medical Center, Rostock, Germany (B.K.); Weill Cornell Medicine, New York, NY (S.T.T.); Novartis Pharmaceuticals, East Hanover, NJ (S.G.); Novartis Pharmaceuticals, Indianapolis, Ind (M.B.); Novartis Pharmaceuticals, Cambridge, Mass (C.C.W.); Novartis Pharmaceuticals, Geneva, Switzerland (A.M.C.); Novartis Pharmaceuticals, St. George, Utah (T.B.); Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (A.J.A.); and University Hospital Essen and German Cancer Consortium, Hufelandstr. 55, 45147 Essen, Germany (K.H.).

المصدر: Radiology [Radiology] 2024 Aug; Vol. 312 (2), pp. e233460.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Radiological Society of North America Country of Publication: United States NLM ID: 0401260 Publication Model: Print Cited Medium: Internet ISSN: 1527-1315 (Electronic) Linking ISSN: 00338419 NLM ISO Abbreviation: Radiology Subsets: MEDLINE

مواضيع طبية MeSH: Gallium Radioisotopes* , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Positron Emission Tomography Computed Tomography*/methods , Lutetium*/therapeutic use , Gallium Isotopes* , Heterocyclic Compounds, 1-Ring*/therapeutic use , Dipeptides*/therapeutic use , Radiopharmaceuticals*/therapeutic use, Humans ; Male ; Aged ; Middle Aged ; Treatment Outcome ; Radioisotopes/therapeutic use ; Edetic Acid/analogs & derivatives ; Edetic Acid/therapeutic use ; Prostate-Specific Antigen

المؤلفون: Zlatanovska I; Institute of Physics, Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje, Skopje, Macedonia., Stafilov T; Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje, Skopje, Macedonia., Šajn R; Geological Survey of Slovenia, Ljubljana, Slovenia., Gonovska BD; Scientific Tobacco Institute, St. Kliment Ohridski University, Prilep, Macedonia., Dimovska S; Institute for Public Health of the Republic of Macedonia, Skopje, Macedonia., Janusheski J; Institute for Public Health of the Republic of Macedonia, Skopje, Macedonia., Memeti S; Institute for Public Health of the Republic of Macedonia, Skopje, Macedonia., Barandovski L; Institute of Physics, Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje, Skopje, Macedonia.

المصدر: Isotopes in environmental and health studies [Isotopes Environ Health Stud] 2024 Aug; Vol. 60 (4), pp. 453-470. Date of Electronic Publication: 2024 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 9602611 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2639 (Electronic) Linking ISSN: 10256016 NLM ISO Abbreviation: Isotopes Environ Health Stud Subsets: MEDLINE

مواضيع طبية MeSH: Soil Pollutants, Radioactive*/analysis , Radiation Monitoring*/methods , Potassium Radioisotopes*/analysis , Radium*/analysis , Cities* , Thorium*/analysis, Cesium Radioisotopes/analysis ; Radiation Dosage ; Spectrometry, Gamma ; Humans ; Gamma Rays

المؤلفون: Larionova N; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Toporova A; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Krivitskiy P; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Polevik V; Shakarim State University, Semey, Kazakhstan., Lechshenko N; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Monayenko V; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Abisheva M; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Baklanov V; Branch 'Institute of Atomic Energy' RSE NNC RK, Kurchatov, Kazakhstan., Aidarkhanov A; Branch 'Institute of Radiation Safety ad Ecology' RSE NNC RK, Kurchatov, Kazakhstan., Vityuk V; National Nuclear Center of the Republic of Kazakhstan, Kurchatov, Kazakhstan.

المصدر: PloS one [PLoS One] 2024 Jul 02; Vol. 19 (7), pp. e0306531. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Radiation Monitoring*/methods , Radioisotopes*/analysis, Plants/chemistry ; Plants/metabolism ; Soil Pollutants, Radioactive/analysis ; Cesium Radioisotopes/analysis ; Nuclear Reactors ; Nuclear Power Plants

المؤلفون: Li JL; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Gan CD; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Du XY; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Yuan XY; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China., Zhong WL; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Yang MQ; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China., Liu R; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Li XY; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China., Wang H; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China.; College of Forestry, Northeast Forestry University, Haerbin, 150000, China., Liao YL; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China., Wang Z; College of Civil Engineering, Northwest Minzu University, Lanzhou, 730000, China., Xu MC; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China., Yang JY; College of Architecture and Environment, Sichuan University, Chengdu, 610065, China. yanyang@scu.edu.cn.; Yibin Institute of Industrial Technology, Sichuan University Yibin Park, Yibin, 644000, China. yanyang@scu.edu.cn.

المصدر: Environmental geochemistry and health [Environ Geochem Health] 2024 Jul 02; Vol. 46 (8), pp. 270. Date of Electronic Publication: 2024 Jul 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8903118 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-2983 (Electronic) Linking ISSN: 02694042 NLM ISO Abbreviation: Environ Geochem Health Subsets: MEDLINE

مواضيع طبية MeSH: Mining* , Soil Pollutants, Radioactive*/analysis , Cesium Radioisotopes*/analysis, Risk Assessment ; China ; Humans ; Strontium Radioisotopes/analysis ; Cesium/analysis ; Cities ; Soil/chemistry ; Monte Carlo Method ; Radiation Monitoring

المؤلفون: Wang R; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.; Department of Nuclear Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China., Jin W; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.; Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518000, China., Luo Y; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Hong H; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Zhao R; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Li L; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Yan L; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Qiao J; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Ploessl K; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.; Five Eleven Pharma Inc., Philadelphia, Pennsylvania 19104, United States., Zhu L; Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China., Kung HF; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.; Five Eleven Pharma Inc., Philadelphia, Pennsylvania 19104, United States.

المصدر: Molecular pharmaceutics [Mol Pharm] 2024 Jul 01; Vol. 21 (7), pp. 3256-3267. Date of Electronic Publication: 2024 Jun 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/metabolism , Gallium Radioisotopes* , Lutetium*/chemistry , Antigens, Surface*/metabolism , Radiopharmaceuticals*/chemistry , Radiopharmaceuticals*/pharmacology , Radiopharmaceuticals*/pharmacokinetics , Glutamate Carboxypeptidase II*/metabolism , Glutamate Carboxypeptidase II*/antagonists & inhibitors, Male ; Humans ; Cell Line, Tumor ; Radioisotopes/chemistry ; Animals ; Chelating Agents/chemistry ; Prostate-Specific Antigen/metabolism ; Tissue Distribution ; Mice ; Edetic Acid/analogs & derivatives ; Edetic Acid/chemistry ; Positron Emission Tomography Computed Tomography/methods